Graciotti M - Search Results

1

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?

Martin Lluesma S, Graciotti M, Chiang CL, Kandalaft LE. Martin Lluesma S, et al. Among authors: graciotti m. Vaccines (Basel). 2018 Nov 23;6(4):79. doi: 10.3390/vaccines6040079. Vaccines (Basel). 2018. PMID: 30477198 Free PMC article. Review.

2

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Graciotti M, Berti C, Klok HA, Kandalaft L. Graciotti M, et al. J Transl Med. 2017 Jun 19;15(1):142. doi: 10.1186/s12967-017-1244-2. J Transl Med. 2017. PMID: 28629381 Free PMC article. Review.

3

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.

Mookerjee A, Graciotti M, Kandalaft LE, Kandalaft L. Mookerjee A, et al. Among authors: graciotti m. Bioimpacts. 2018;8(3):211-221. doi: 10.15171/bi.2018.24. Epub 2018 Jun 10. Bioimpacts. 2018. PMID: 30211081 Free PMC article.

4

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine.

Mookerjee A, Graciotti M, Kandalaft LE. Mookerjee A, et al. Among authors: graciotti m. Cancers (Basel). 2019 Jan 4;11(1):40. doi: 10.3390/cancers11010040. Cancers (Basel). 2019. PMID: 30621204 Free PMC article.

5

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.

Mookerjee A, Graciotti M, Kandalaft LE. Mookerjee A, et al. Among authors: graciotti m. Bioimpacts. 2019;9(1):65. doi: 10.15171/bi.2019.08. Epub 2019 Jan 12. Bioimpacts. 2019. PMID: 30788261 Free PMC article.

6

Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.

Ahmed R, Sayegh N, Graciotti M, Kandalaft LE. Ahmed R, et al. Among authors: graciotti m. Curr Opin Biotechnol. 2020 Oct;65:142-155. doi: 10.1016/j.copbio.2020.02.009. Epub 2020 Mar 30. Curr Opin Biotechnol. 2020. PMID: 32240923 Review.

7

Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?

Martin-Lluesma S, Graciotti M, Grimm AJ, Boudousquié C, Chiang CL, Kandalaft LE. Martin-Lluesma S, et al. Among authors: graciotti m. Curr Opin Biotechnol. 2020 Oct;65:190-196. doi: 10.1016/j.copbio.2020.03.003. Epub 2020 Apr 22. Curr Opin Biotechnol. 2020. PMID: 32334152 Review.

8

Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines.

Graciotti M, Marino F, Pak H, Baumgaertner P, Thierry AC, Chiffelle J, Perez MAS, Zoete V, Harari A, Bassani-Sternberg M, Kandalaft LE. Graciotti M, et al. Vaccines (Basel). 2020 Jun 2;8(2):271. doi: 10.3390/vaccines8020271. Vaccines (Basel). 2020. PMID: 32498431 Free PMC article.

9

Antitumour dendritic cell vaccination in a priming and boosting approach.

Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE. Harari A, et al. Among authors: graciotti m. Nat Rev Drug Discov. 2020 Sep;19(9):635-652. doi: 10.1038/s41573-020-0074-8. Epub 2020 Aug 6. Nat Rev Drug Discov. 2020. PMID: 32764681 Review.

10

Editorial overview: Pharmaceutical biotechnology: new frontiers in cancer immunotherapy.

Kandalaft LE, Graciotti M. Kandalaft LE, et al. Among authors: graciotti m. Curr Opin Biotechnol. 2020 Oct;65:iii-v. doi: 10.1016/j.copbio.2020.08.013. Epub 2020 Sep 8. Curr Opin Biotechnol. 2020. PMID: 32917468 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters